Cargando…
Glutamatergic and GABAergic reactivity and cognition in 22q11.2 deletion syndrome and healthy volunteers: A randomized double-blind 7-Tesla pharmacological MRS study
AIMS: 22q11.2 deletion syndrome (22q11.2DS) is associated with impaired cognitive functioning. Glutamatergic pathways have been linked with cognition and are hypothesized to be disrupted in 22q11.2DS patients, possibly ‘shifting’ the excitatory (glutamate)/inhibitory (GABA) balance. Hence, the gluta...
Autores principales: | , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
SAGE Publications
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7376622/ https://www.ncbi.nlm.nih.gov/pubmed/32448020 http://dx.doi.org/10.1177/0269881120922977 |
_version_ | 1783562072699699200 |
---|---|
author | Vingerhoets, Claudia Tse, Desmond HY van Oudenaren, Mathilde Hernaus, Dennis van Duin, Esther Zinkstok, Janneke Ramaekers, Johannes G Jansen, Jacobus FA McAlonan, Grainne van Amelsvoort, Therese |
author_facet | Vingerhoets, Claudia Tse, Desmond HY van Oudenaren, Mathilde Hernaus, Dennis van Duin, Esther Zinkstok, Janneke Ramaekers, Johannes G Jansen, Jacobus FA McAlonan, Grainne van Amelsvoort, Therese |
author_sort | Vingerhoets, Claudia |
collection | PubMed |
description | AIMS: 22q11.2 deletion syndrome (22q11.2DS) is associated with impaired cognitive functioning. Glutamatergic pathways have been linked with cognition and are hypothesized to be disrupted in 22q11.2DS patients, possibly ‘shifting’ the excitatory (glutamate)/inhibitory (GABA) balance. Hence, the glutamate/GABA balance may constitute a target for pharmacological treatment. We aimed to examine alterations of glutamate/GABA metabolites in 22q11.2DS in vivo using riluzole, a compound with glutamate/GABA-modulating action, as pharmacological challenge. METHODS: Seventeen 22q11.2DS patients and 20 matched healthy controls were enrolled in this randomized double-blind placebo-controlled crossover study. Glutamate and glutamine concentrations in the anterior cingulate cortex (ACC) and striatum, as well as ACC GABA concentrations were obtained after placebo and after a single dose of 50 mg riluzole using 7-Tesla magnetic resonance spectroscopy (MRS). Within the 22q11.2DS group, the relationship between metabolite concentrations and cognition was examined. RESULTS: No group differences were found in ACC and striatal metabolite concentrations following placebo. Riluzole numerically decreased ACC (η(2) = 0.094) but not striatal glutamate concentrations as well as ACC GABA concentrations (η(2) = 0.176) in all subjects. In both regions, riluzole did not alter glutamine concentration. No interaction effects were found. Although not significant after Bonferroni correction, ACC glutamate concentrations were inversely correlated with cognitive functions in 22q11.2DS patients. DISCUSSION: We did not demonstrate altered ACC and striatal metabolite concentrations in 22q11.2DS. Nevertheless, these results suggest that glutamate and GABA can be modulated with a single dose of riluzole. Possibly, riluzole may have memory-enhancing effects in 22q11.2DS. Future studies should examine the long-term effects of riluzole on cognition. |
format | Online Article Text |
id | pubmed-7376622 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2020 |
publisher | SAGE Publications |
record_format | MEDLINE/PubMed |
spelling | pubmed-73766222020-08-13 Glutamatergic and GABAergic reactivity and cognition in 22q11.2 deletion syndrome and healthy volunteers: A randomized double-blind 7-Tesla pharmacological MRS study Vingerhoets, Claudia Tse, Desmond HY van Oudenaren, Mathilde Hernaus, Dennis van Duin, Esther Zinkstok, Janneke Ramaekers, Johannes G Jansen, Jacobus FA McAlonan, Grainne van Amelsvoort, Therese J Psychopharmacol Original Papers AIMS: 22q11.2 deletion syndrome (22q11.2DS) is associated with impaired cognitive functioning. Glutamatergic pathways have been linked with cognition and are hypothesized to be disrupted in 22q11.2DS patients, possibly ‘shifting’ the excitatory (glutamate)/inhibitory (GABA) balance. Hence, the glutamate/GABA balance may constitute a target for pharmacological treatment. We aimed to examine alterations of glutamate/GABA metabolites in 22q11.2DS in vivo using riluzole, a compound with glutamate/GABA-modulating action, as pharmacological challenge. METHODS: Seventeen 22q11.2DS patients and 20 matched healthy controls were enrolled in this randomized double-blind placebo-controlled crossover study. Glutamate and glutamine concentrations in the anterior cingulate cortex (ACC) and striatum, as well as ACC GABA concentrations were obtained after placebo and after a single dose of 50 mg riluzole using 7-Tesla magnetic resonance spectroscopy (MRS). Within the 22q11.2DS group, the relationship between metabolite concentrations and cognition was examined. RESULTS: No group differences were found in ACC and striatal metabolite concentrations following placebo. Riluzole numerically decreased ACC (η(2) = 0.094) but not striatal glutamate concentrations as well as ACC GABA concentrations (η(2) = 0.176) in all subjects. In both regions, riluzole did not alter glutamine concentration. No interaction effects were found. Although not significant after Bonferroni correction, ACC glutamate concentrations were inversely correlated with cognitive functions in 22q11.2DS patients. DISCUSSION: We did not demonstrate altered ACC and striatal metabolite concentrations in 22q11.2DS. Nevertheless, these results suggest that glutamate and GABA can be modulated with a single dose of riluzole. Possibly, riluzole may have memory-enhancing effects in 22q11.2DS. Future studies should examine the long-term effects of riluzole on cognition. SAGE Publications 2020-05-25 2020-08 /pmc/articles/PMC7376622/ /pubmed/32448020 http://dx.doi.org/10.1177/0269881120922977 Text en © The Author(s) 2020 http://creativecommons.org/licenses/by/4.0/ This article is distributed under the terms of the Creative Commons Attribution 4.0 License (http://www.creativecommons.org/licenses/by/4.0/) which permits any use, reproduction and distribution of the work without further permission provided the original work is attributed as specified on the SAGE and Open Access page (https://us.sagepub.com/en-us/nam/open-access-at-sage). |
spellingShingle | Original Papers Vingerhoets, Claudia Tse, Desmond HY van Oudenaren, Mathilde Hernaus, Dennis van Duin, Esther Zinkstok, Janneke Ramaekers, Johannes G Jansen, Jacobus FA McAlonan, Grainne van Amelsvoort, Therese Glutamatergic and GABAergic reactivity and cognition in 22q11.2 deletion syndrome and healthy volunteers: A randomized double-blind 7-Tesla pharmacological MRS study |
title | Glutamatergic and GABAergic reactivity and cognition in 22q11.2 deletion syndrome and healthy volunteers: A randomized double-blind 7-Tesla pharmacological MRS study |
title_full | Glutamatergic and GABAergic reactivity and cognition in 22q11.2 deletion syndrome and healthy volunteers: A randomized double-blind 7-Tesla pharmacological MRS study |
title_fullStr | Glutamatergic and GABAergic reactivity and cognition in 22q11.2 deletion syndrome and healthy volunteers: A randomized double-blind 7-Tesla pharmacological MRS study |
title_full_unstemmed | Glutamatergic and GABAergic reactivity and cognition in 22q11.2 deletion syndrome and healthy volunteers: A randomized double-blind 7-Tesla pharmacological MRS study |
title_short | Glutamatergic and GABAergic reactivity and cognition in 22q11.2 deletion syndrome and healthy volunteers: A randomized double-blind 7-Tesla pharmacological MRS study |
title_sort | glutamatergic and gabaergic reactivity and cognition in 22q11.2 deletion syndrome and healthy volunteers: a randomized double-blind 7-tesla pharmacological mrs study |
topic | Original Papers |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7376622/ https://www.ncbi.nlm.nih.gov/pubmed/32448020 http://dx.doi.org/10.1177/0269881120922977 |
work_keys_str_mv | AT vingerhoetsclaudia glutamatergicandgabaergicreactivityandcognitionin22q112deletionsyndromeandhealthyvolunteersarandomizeddoubleblind7teslapharmacologicalmrsstudy AT tsedesmondhy glutamatergicandgabaergicreactivityandcognitionin22q112deletionsyndromeandhealthyvolunteersarandomizeddoubleblind7teslapharmacologicalmrsstudy AT vanoudenarenmathilde glutamatergicandgabaergicreactivityandcognitionin22q112deletionsyndromeandhealthyvolunteersarandomizeddoubleblind7teslapharmacologicalmrsstudy AT hernausdennis glutamatergicandgabaergicreactivityandcognitionin22q112deletionsyndromeandhealthyvolunteersarandomizeddoubleblind7teslapharmacologicalmrsstudy AT vanduinesther glutamatergicandgabaergicreactivityandcognitionin22q112deletionsyndromeandhealthyvolunteersarandomizeddoubleblind7teslapharmacologicalmrsstudy AT zinkstokjanneke glutamatergicandgabaergicreactivityandcognitionin22q112deletionsyndromeandhealthyvolunteersarandomizeddoubleblind7teslapharmacologicalmrsstudy AT ramaekersjohannesg glutamatergicandgabaergicreactivityandcognitionin22q112deletionsyndromeandhealthyvolunteersarandomizeddoubleblind7teslapharmacologicalmrsstudy AT jansenjacobusfa glutamatergicandgabaergicreactivityandcognitionin22q112deletionsyndromeandhealthyvolunteersarandomizeddoubleblind7teslapharmacologicalmrsstudy AT mcalonangrainne glutamatergicandgabaergicreactivityandcognitionin22q112deletionsyndromeandhealthyvolunteersarandomizeddoubleblind7teslapharmacologicalmrsstudy AT vanamelsvoorttherese glutamatergicandgabaergicreactivityandcognitionin22q112deletionsyndromeandhealthyvolunteersarandomizeddoubleblind7teslapharmacologicalmrsstudy |